Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 18/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | PARP1 | P09874 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20845592 | 0.80 | PARP1 (0.74) | PIM1ALDH1A1PARP1 | |
| SCHEMBL7330187 | 0.79 | GABRP (0.47) | PIM1ALDH1A1PARP1 | |
| SCHEMBL27926381 | 0.79 | PARP1 (0.72) | PIM1ALDH1A1PARP1 | |
| SCHEMBL8668423 | 0.78 | PARP1 (0.41) | PIM1ALDH1A1PARP1 | |
| SCHEMBL10721784 | 0.78 | KDM4A (0.60) | PIM1PARP1 | |
| SCHEMBL31654039 | 0.77 | ALDH1A1 (0.57) | PIM1ALDH1A1PARP1 | |
| SCHEMBL3225103 | 0.77 | ALDH1A1 (0.57) | PIM1ALDH1A1PARP1 | |
| SCHEMBL24834805 | 0.75 | GABRP (0.47) | ALDH1A1PARP1 | |
| SCHEMBL1997423 | 0.75 | SMN1; SMN2 (0.57) | ALDH1A1PARP1 | |
| SCHEMBL311735 | 0.75 | GABRP (0.47) | ALDH1A1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280849-A1 | Synergic Combinations Comprising a Quinoline Compound and Other Hiv Infection Therapeutic Agents | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2008-11-13 | — | — | US | disclosed |
| US-20080161350-A1 | USE OF QUINOLINE DERIVATIVES WITH ANTI-INTEGRASE EFFECT AND APPLICATIONS THEREOF | BIOALLIANCE PHARMA SA | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280849-A1 | Synergic Combinations Comprising a Quinoline Compound and Other Hiv Infection Therapeutic Agents | CTSL, CDKL1, QTRT2 | PIM1 1303/4885ALDH1A1 2239/4885PARP1 60/4885 |
| US-20080161350-A1 | USE OF QUINOLINE DERIVATIVES WITH ANTI-INTEGRASE EFFECT AND APPLICATIONS THEREOF | TYMP, CDK7, MAVS | PIM1 171/4885ALDH1A1 853/4885PARP1 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.